HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Postmarketing guidance

This article was originally published in The Tan Sheet

Executive Summary

An updated guidance for industry "provides recommendations on procedures, content and format for submitting a postmarketing study status report," FDA announces in the Feb. 16 Federal Register. "Reports on the Status of Postmarketing Study Commitments" also provides "timeframes for FDA's review of postmarketing study commitments; and information about postmarketing study commitments that will be available to the public." The guidance replaces an April 2001 version of the guidance, which was published following the issuance of a final rule on postmarketing study status reports in October 2001 (1"The Tan Sheet" April 16, 2001, p. 6). The overall status of a company's postmarketing commitment is still determined by the study which has made the least progress, according to the guidance...

You may also be interested in...



Postmarketing Study Status To Be Defined By Trial Making Least Progress

The overall status of a company's postmarketing commitment for a product will be determined by the study which has made the least progress, according to an FDA draft guidance.

Swiss Biotechs May Get SPAC Listing Option Soon

Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.

Novartis Q1 Preview: Profits Still Under Pressure From Lockdown

The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular. 

Topics

UsernamePublicRestriction

Register

RS125594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel